Colgate-Palmolive Company
CL
$92.98
-1.16%
Colgate-Palmolive is a global leader in household and personal care products, best known for its oral care line (over 40% of sales), along with shampoos, deodorants, and home care items sold in over 200 countries. The company also owns Hill's Pet Nutrition, a specialty pet food brand that contributes nearly one-fourth of total revenue and sells primarily through veterinarians. As a defensive consumer staples giant with a strong emerging market presence (about 70% of sales international, half from emerging regions), Colgate is currently attracting investor attention for its steady revenue growth, margin resilience, and consistent cash generation amid a rotation toward value and defensive stocks.…
CL
Colgate-Palmolive Company
$92.98
Investment Opinion: Should I buy CL Today?
Rating: Hold. Colgate-Palmolive is a high-quality defensive stock with accelerating revenue growth and strong cash flows, but its premium valuation and limited upside to analyst targets (3.9%) suggest the stock is fairly valued. The consensus analyst rating is Buy with an average target of $96.60, but the risk/reward is balanced.
Supporting Evidence: Revenue grew 8.41% YoY in Q1 2026, accelerating from prior quarters. Gross margin improved to 60.6% from 59.4% in Q3 2025. Free cash flow of $3.767B provides a 5.9% yield. The forward P/E of 22.9x is in line with the industry average, but the trailing P/E of 29.9x indicates a premium. ROE of 39.5% reflects efficient capital use.
Risks & Conditions: The Hold rating would upgrade to Buy if the forward P/E compresses below 20x or if revenue growth sustains above 8%. It would downgrade to Sell if revenue growth decelerates below 4% or gross margins fall below 58%. Overall, CL appears fairly valued relative to its history and peers, with limited upside but strong downside protection.
Sign up to view all
CL 12-Month Price Forecast
Colgate-Palmolive's strong operational momentum is offset by a premium valuation that limits upside. The base case of 5-7% growth and stable margins is most likely, leading to a neutral stance. The stock offers defensive qualities and decent income, but capital appreciation potential is modest. An upgrade to bullish would require evidence of sustained high growth or a valuation pullback, while a downgrade would follow margin deterioration or a growth slowdown.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $97.30 and implied upside of +4.7% versus the current price.
Average Target
$97.30
0 analysts
Implied Upside
+4.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $110
Analyst target range
Colgate-Palmolive is covered by 20 analysts, with a consensus recommendation of 'Buy' (mean score 2.1 on a 1-5 scale where 1 is Strong Buy). The average target price is $96.60, implying a 3.9% upside from the current price of $92.98. The distribution leans bullish: 10 recent ratings include 7 Buy/Overweight and 3 Hold/Equal Weight, with no Sell ratings. The target price range spans from $80.00 (low) to $110.00 (high). The low target of $80.00 assumes potential margin compression or competitive pressures, while the high target of $110.00 (+18.3% upside) reflects optimism about continued growth and multiple expansion. The spread of $30 (27% of the average target) indicates moderate uncertainty. Recent analyst actions are positive: Citigroup, UBS, RBC Capital, JP Morgan, and Morgan Stanley have reiterated Buy/Overweight ratings, while Rothschild & Co upgraded from Neutral to Buy in April 2026. No downgrades have been reported recently, reinforcing the bullish consensus.
Drowning in data?
Find the real signal!
Bulls vs Bears: CL Investment Factors
Colgate-Palmolive presents a balanced risk/reward profile. The bull case is supported by accelerating revenue growth (8.41% YoY), strong free cash flow ($3.767B), and a defensive beta of 0.319, making it a safe haven in volatile markets. However, the bear case highlights a premium valuation (trailing P/E 29.9x vs industry ~22x) and limited upside to analyst targets (3.9%). The single most important tension is whether the company can sustain its revenue acceleration and margin expansion to justify its premium multiple. If growth decelerates or margins compress, the stock could re-rate lower. Currently, the evidence slightly favors the bull case given the strong operational momentum and defensive characteristics, but the valuation limits aggressive upside.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 8.41% YoY to $5.324B, accelerating from 5.8% in Q4 2025 and 4.7% in Q3 2025. This consistent acceleration signals strong demand across oral care and pet nutrition segments.
- Strong Free Cash Flow Generation: TTM free cash flow stands at $3.767B, yielding 5.9% relative to market cap. This robust cash generation supports dividend payments (2.85% yield) and debt servicing despite a 147.9% debt-to-equity ratio.
- Defensive Low Beta Profile: With a beta of 0.319, CL is 68% less volatile than the S&P 500. This makes it a portfolio stabilizer during market downturns, as evidenced by its 1-year relative strength outperforming the S&P 500 by 6.58% vs 18.35%.
- Improving Gross Margins: Gross margin improved to 60.6% in Q1 2026 from 59.4% in Q3 2025, indicating pricing power and effective cost management. Operating margin of 21.7% remains healthy and stable.
Bearish
- Elevated Valuation vs Peers: Trailing P/E of 29.9x is above the household products industry average of ~22x, suggesting a premium. While forward P/E of 22.9x is more reasonable, the stock still trades at a premium to the sector.
- High Debt-to-Equity Ratio: Debt-to-equity of 147.9% is elevated for a consumer staples company, increasing financial risk. Although free cash flow covers interest, a rising rate environment could pressure earnings.
- Low Dividend Growth Potential: Payout ratio of 85.5% leaves limited room for dividend increases. The current yield of 2.85% is decent but not exceptional for income-focused investors.
- Limited Upside to Analyst Targets: Average analyst target of $96.60 offers only 3.9% upside from $92.98, with the low target of $80 implying a 14% downside. The narrow upside suggests limited near-term appreciation.
CL Technical Analysis
Colgate-Palmolive is in a sustained uptrend over the past year, with a 1-year price change of +6.58%. The current price of $92.98 sits at 83.5% of its 52-week range ($74.55 low to $99.33 high), indicating the stock is trading near the upper end of its range, reflecting positive momentum but not overextended. The stock's beta of 0.319 suggests it is significantly less volatile than the market, making it a defensive holding. Short-term momentum is accelerating: the 1-month change is +2.65% and the 3-month change is +8.36%, both outpacing the S&P 500's respective gains of 0.31% and 4.67%. This divergence from the broader market's slower pace signals relative strength and a potential rotation into defensive names. The 1-month relative strength of +2.34% confirms this outperformance. Key support lies near the 52-week low of $74.55, while resistance is at the 52-week high of $99.33. A breakout above $99.33 would signal a new uptrend leg, while a breakdown below $74.55 would be a bearish reversal. With a beta of 0.319, the stock is about 68% less volatile than the S&P 500, making it suitable for risk-averse portfolios.
Beta
0.32
0.32x market volatility
Max Drawdown
-19.7%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+6.6%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +2.6% | -0.5% |
| 3m | +8.4% | +4.9% |
| 6m | +10.0% | +9.7% |
| 1y | +6.6% | +18.4% |
| ytd | +19.7% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue growth is solid and accelerating: Q1 2026 revenue was $5.324 billion, up 8.41% year-over-year, following a 5.8% increase in Q4 2025 and 4.7% in Q3 2025. The Oral, Personal and Home Care segment contributed $4.034 billion (76% of total) and Pet Nutrition $1.196 billion (22%), with both segments driving growth. The accelerating top-line trend supports the investment case for steady expansion. Profitability is robust: Q1 2026 net income was $646 million, with a net margin of 12.1%, up from 14.0% in Q1 2025 but down from 14.5% in Q2 2025. Gross margin improved to 60.6% in Q1 2026 from 59.4% in Q3 2025, indicating pricing power and cost control. Operating margin of 21.7% is healthy and stable, typical for the household products industry. The balance sheet is strong: free cash flow (TTM) of $3.767 billion provides ample liquidity, with a free cash flow yield of 5.9%. Debt-to-equity is 147.9%, elevated but manageable given strong cash generation. ROE is 39.5%, reflecting efficient use of equity. The current ratio of 1.0 suggests adequate short-term liquidity.
Quarterly Revenue
$5.3B
2026-03
Revenue YoY Growth
+8.4%
YoY Comparison
Gross Margin
60.6%
Latest Quarter
Free Cash Flow
$3.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 29.9x, while the forward P/E is 22.9x, implying the market expects earnings growth to reduce the multiple. The gap between trailing and forward P/E suggests anticipated earnings expansion. Compared to the industry average (not provided, but typically ~22x for household products), Colgate's trailing P/E of 29.9x appears at a premium. However, its forward P/E of 22.9x is more in line with the sector, indicating that growth expectations justify the current valuation. Historically, Colgate's trailing P/E has ranged from about 22x to 42x over the past five years. At 29.9x, it is near the lower end of its historical range, suggesting the stock is not overvalued relative to its own history. This could indicate a value opportunity if fundamentals remain strong.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Colgate's debt-to-equity of 147.9% is high for a consumer staples firm, though TTM free cash flow of $3.767B provides ample coverage. The payout ratio of 85.5% leaves minimal room for dividend growth, and any earnings shock could force a cut. Revenue concentration in oral care (over 40% of sales) and pet nutrition (22%) exposes the company to segment-specific downturns. The Q4 2025 net loss of $37M due to a $970M other expense charge demonstrates that non-recurring items can materially impact reported earnings.
Market & Competitive Risks: The trailing P/E of 29.9x is above the industry average of ~22x, making the stock vulnerable to multiple compression if growth slows. With a beta of 0.319, CL is less sensitive to macro swings, but a sustained rotation out of defensive stocks could still pressure the stock. Competition from private labels and emerging-market rivals could erode market share. Recent news highlights a rotation into value stocks, which could benefit CL but also attract profit-taking after its 19.7% YTD gain.
Worst-Case Scenario: A combination of slowing revenue growth (below 4%), margin compression from input cost inflation, and a broader market sell-off could drive CL to its 52-week low of $74.55, representing a 19.8% decline from the current price of $92.98. This scenario would likely require a recession or company-specific misstep, such as a major product recall or regulatory action. The analyst low target of $80 implies a 14% downside, while the historical max drawdown of -19.66% suggests a realistic worst-case loss of about 20%.
FAQ
The key risks include: (1) Valuation risk: trailing P/E of 29.9x is above the industry average, making the stock vulnerable to multiple compression if growth slows. (2) Financial risk: debt-to-equity of 147.9% is high, though free cash flow covers interest. (3) Competitive risk: private labels and emerging-market rivals could pressure market share and margins. (4) Company-specific risk: the Q4 2025 net loss of $37M due to a $970M other expense charge highlights potential earnings volatility from non-recurring items. The most severe risk is a growth deceleration below 4%, which could trigger a re-rating to the 52-week low of $74.55.
The 12-month forecast is neutral to slightly bullish. The base case (50% probability) sees the stock trading between $93 and $100, with revenue growth of 5-7% and stable margins. The bull case (25% probability) targets $100-$110, driven by sustained high growth and multiple expansion. The bear case (25% probability) targets $75-$85, assuming growth deceleration and margin compression. The most likely scenario is the base case, with the stock near the analyst average target of $96.60. Key catalysts include the next earnings report and any changes in consumer spending trends.
CL appears fairly valued to slightly overvalued based on current metrics. The trailing P/E of 29.9x is above the household products industry average of ~22x, indicating a premium. However, the forward P/E of 22.9x is more in line with the sector, suggesting that expected earnings growth justifies the valuation. Historically, CL's trailing P/E has ranged from 22x to 42x over the past five years, so at 29.9x it is near the lower end of its historical range, implying it is not overvalued relative to its own history. The market is pricing in steady growth and defensive qualities, which is reasonable given the company's performance.
CL is a good buy for conservative investors seeking stable income and low volatility. The stock offers a 2.85% dividend yield, a beta of 0.319, and accelerating revenue growth of 8.41% YoY. However, with a trailing P/E of 29.9x and only 3.9% upside to the average analyst target of $96.60, the risk/reward is balanced. It is best suited as a long-term core holding rather than a short-term trade. For growth-oriented investors, the limited upside may not be compelling, but for those prioritizing capital preservation and income, CL is a solid choice.
CL is best suited for long-term investment due to its defensive nature, low beta of 0.319, and consistent dividend payments. The stock's 1-year price change of +6.58% and YTD gain of 19.68% indicate steady appreciation, but short-term upside is limited given the 3.9% analyst target upside. For short-term traders, the low volatility and narrow trading range (52-week range $74.55-$99.33) offer limited profit potential. A minimum holding period of 3-5 years is recommended to benefit from compounding dividends and gradual earnings growth. The stock is ideal for income-focused and risk-averse portfolios.
